Argus has downgraded Silk Road Medical to hold after CMS covered a competing product. Read more here.
Oppenheimer has initiated coverage on Silk Road Medical Inc (NASDAQ: SILK ) with an Outperform rating and price target of $30 . Analysts Suraj Kalia and Shaymus Contorno note that Silk Road Medical has been at the forefront of introducing the Transcarotid Artery Revascularization (TCAR) method, an innovative procedure for stroke prevention in patients with carotid stenosis. Since its approval in 2015, SILK''s revenues have grown impressively, with a four-year CAGR of 42%, leading to yearly sales of around $182 … Full story available on Benzinga.com
The outlook for Silk Road Medical is mixed, with potential capital budgeting constraints and exogenous risks from the marketplace. See why SILK stock is a Hold.
SUNNYVALE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming UBS MedTech, Tools and Genomics Summit .
Silk Road Medical press release (SILK): Q2 GAAP EPS of -$0.35 beats by $0.03.Revenue of $45.3M (+36.6% Y/Y) beats by $2.13M.2023 Financial GuidanceSilk Road Medical projects revenue…
SUNNYVALE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2023.